BioSpace News Archive

Basecare, an innovative assisted reproductive genetic testing enterprise, officially listed on the main board of HKEX.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus, announced the expansion of its R&D pipeline with six new armed gene therapy/oncolytic constructs directed against important cancer targets and indications.

NanoViricides, Inc. has announced today that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections was well tolerated in safety pharmacology studies required for progressing to human clinical trials.

Puzzle Medical Devices Inc., ( www.puzzlemed.com ) announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its revolutionary transcatheter pump to address heart failure.

These Additional Classifications are: Tauri-Gum™ Cases (8 Retail Boxes) & Tauri-Gum™ Shipment Crates (48 Retail Boxes)

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced the appointment of William H. Carson, M.D. to its board of directors.

OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and therapeutics.

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that on January 25, 2021, the National Medical Products Administration (the “NMPA”)

Today, the Sarah Cannon Transplant and Cellular Therapy Network, formerly the Sarah Cannon Blood Cancer Network, announced 19 abstracts and presentations have been accepted for presentation at the 2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held virtually from February 8-12, 2021.

Vedanta Biosciences , a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced the appointment of Mark Mullikin as Chief Financial Officer.